Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Unite reiterates FY25 guidance following 'continued momentum'

(Sharecast News) - Student accommodation provider Unite reiterated its FY25 guidance for adjusted EPRA earnings per share of 47.5p to 48.25p on Tuesday as it said it had seen "continuing momentum", with 85% of beds sold for the 2025/26 academic year. Unite said the outlook for student demand was "strong", with 2% growth in applications from UK 18-year-olds and student visa applications up 29% over the first five months of the year.

The FTSE 100-listed firm said this had translated into improving momentum in sales for its accommodation and said demand from universities remained "strong", resulting in nomination agreements for 56% of beds for the 2025/26 academic year.

Unite also noted that it expects "a later sales cycle", in line with historical trends, supported by "strong demand" from UK students following A-Level results in mid-August and from international students during September. It also noted that sales to date supported rental growth of 4-5% for the 2025/26 academic year and said it continues to target occupancy of 97-98%.

Chief executive Joe Lister said: "Student numbers are expected to increase for the 2025/26 academic year due to a growing UK 18-year-old population and improving trends in international student recruitment. Sales momentum has picked up in recent weeks, in-line with our expectations for a later sales cycle, and we continue to target occupancy of at least 97%. Demand for our accommodation remains underpinned by our alignment to the UK's strongest universities and nomination agreements with our university partners."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.